Von Hippel Lindau (VHL) Rabbit Polyclonal Antibody

CAT#: TA357585

VHL Antibody - N-terminal region

Product Images

WB Suggested Anti-VHL Antibody Titration: 1.0 ug/ml Positive Control: Hela Whole Cell

Specifications

Product Data

• Applications: WB
• Reactivities: Human
• Host: Rabbit
• Clonality: Polyclonal
• Specificity: Expected reactivity: Cow, Dog, Guinea Pig, Human, Mouse, Rat
  Homology: Cow: 93%; Dog: 93%; Guinea Pig: 100%; Human: 100%; Mouse: 100%; Rat: 100%
• Formulation: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
• Concentration: lot specific
• Purification: Affinity Purified
• Conjugation: Unconjugated
• Storage: For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Predicted Protein Size: 19kDa
• Gene Name: von Hippel-Lindau tumor suppressor
• Database Link:
  NP_937799
  Entrez Gene 7428 Human
  UniProt ID P40337-2
• Background: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
• Synonyms: HRCA1; pVHL; RCA1; VHL1

Reference Data

• Protein Families: Druggable Genome, Transcription Factors
• Protein Pathways: Pathways in cancer, Renal cell carcinoma, Ubiquitin mediated proteolysis